Meanwhile, the efficacy of apatinib as vascular endothelial growth factor (VEGF)-targeted therapy in predicting the outcome of ovarian cancer patients by evaluating the distinct adipose tissue has been reported (22). This evidence concerns the gene VEGFA and ovarian cancer.